---
title: "Cipla Ltd (CIPLA) — Share Price, Financials & Analysis"
symbol: "CIPLA"
company: "Cipla Ltd"
canonical: "https://tapetide.com/stocks/CIPLA"
isin: "INE059A01026"
nse_symbol: "CIPLA"
bse_code: "500087"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 109075.27
generated_at: "2026-09-13T18:20:03.376Z"
---

# Cipla Ltd (CIPLA)

Canonical page: https://tapetide.com/stocks/CIPLA

## Company

- **NSE Symbol:** CIPLA
- **BSE Code:** 500087
- **ISIN:** INE059A01026
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 1995-02-08
- **CEO:** Mr. Umang Vohra B.E., M.B.A.
- **Employees:** 30313
- **Face Value:** ₹2
- **F&O Eligible:** Yes
- **Website:** cipla.com

## About

Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]

## Latest Price

- **Price:** ₹1366
- **Change:** -7.3 (-0.53%)
- **Open:** ₹1373
- **Day High:** ₹1373
- **Day Low:** ₹1347.7
- **Previous Close:** ₹1373.3
- **Volume:** 1681155
- **As Of:** 2026-09-11T10:26:35+00:00

## Key Fundamentals

Observed at 2026-09-11T04:54:38.433926Z.

- **Market Cap:** ₹109075.27 Cr
- **Classification:** Midcap
- **P/E (reported):** 33.2
- **P/E (TTM):** 32.73
- **EPS (TTM):** ₹41.74
- **EPS (reported):** ₹55.04
- **Book Value:** ₹426.21
- **Price to Book:** 3.24
- **Dividend Yield:** 0.95%
- **ROE:** 11.21%
- **ROCE:** 14.88%
- **Debt to Equity:** 0.02
- **Revenue (yearly):** ₹29044.6 Cr
- **Net Income:** ₹3869.8 Cr
- **EBITDA:** ₹6764.9 Cr
- **52-Week High:** ₹1673
- **52-Week Low:** ₹1165.7
- **RSI (14):** 36.94

## Tapetide Score

- **Score:** 50 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Falling
- **Percentile:** 47.7 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 79.35 | 9% |
| growth | 8.22 | 9% |
| momentum | 19.36 | 12% |
| ownership | 49.58 | 24% |
| quality | 45.85 | 22% |
| valuation | 72.71 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 25.7%

### Weaknesses

- The company has delivered a poor sales growth of 8.01% over past five years.
- Promoter holding has decreased over last 3 years: -4.24%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -21.28% | -4.69% | 18.46% |
| ebitda margin growth | 32.62% | -17.18% | -12.25% | 6.2% |
| net income growth | 44.79% | -26.86% | 10% | 10% |
| revenue growth | 10.22% | 2.24% | 7% | 8% |
| roce | 52.59% | -31.02% | -29.41% | 18.16% |
| roe | 44.8% | -33.71% | 14.54% | -7.51% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 6678 | 6604 | 6163 | 6694 | 7051 | 7073 | 6730 | 6957 | 7589 | 7074 | 6541 | 7119 |
| Expenses | 4944 | 4856 | 4847 | 4978 | 5165 | 5084 | 5192 | 5179 | 5695 | 5819 | 5586 | 5927 |
| Operating Profit | 1734 | 1748 | 1316 | 1716 | 1886 | 1989 | 1538 | 1778 | 1895 | 1255 | 955 | 1192 |
| OPM % | 26 | 26 | 21 | 26 | 27 | 28 | 23 | 26 | 25 | 18 | 15 | 17 |
| Other Income | 176 | -10 | 249 | 160 | 191 | 222 | 289 | 259 | 269 | -70 | 148 | 211 |
| Interest | 26 | 30 | 18 | 18 | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 17 |
| Depreciation | 290 | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 | 278 | 383 | 304 |
| Profit before tax | 1594 | 1474 | 1259 | 1611 | 1789 | 1916 | 1504 | 1770 | 1854 | 893 | 707 | 1082 |
| Tax % | 28 | 28 | 26 | 27 | 27 | 17 | 19 | 27 | 27 | 24 | 22 | 27 |
| Net Profit | 1155 | 1068 | 932 | 1175 | 1305 | 1575 | 1214 | 1292 | 1353 | 674 | 543 | 786 |
| EPS in Rs | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 | 15.13 | 16.06 | 16.73 | 8.37 | 6.87 | 9.77 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 15156 | 16362 | 17132 | 19160 | 21763 | 22753 | 25774 | 27548 | 28163 | 28324 |
| Expenses | 12329 | 13265 | 13926 | 14907 | 17211 | 17726 | 19483 | 20420 | 22280 | 23027 |
| Operating Profit | 2826 | 3097 | 3206 | 4252 | 4553 | 5027 | 6291 | 7128 | 5883 | 5297 |
| OPM % | 19 | 19 | 19 | 22 | 21 | 22 | 24 | 26 | 21 | 19 |
| Other Income | 280 | 477 | 344 | 266 | 99 | 293 | 552 | 862 | 606 | 558 |
| Interest | 114 | 168 | 197 | 161 | 106 | 110 | 90 | 62 | 54 | 57 |
| Depreciation | 1323 | 1326 | 1175 | 1068 | 1052 | 1172 | 1051 | 1107 | 1211 | 1262 |
| Profit before tax | 1669 | 2079 | 2178 | 3290 | 3493 | 4038 | 5702 | 6821 | 5224 | 4536 |
| Tax % | 15 | 27 | 29 | 27 | 27 | 30 | 27 | 22 | 26 | — |
| Net Profit | 1417 | 1492 | 1500 | 2389 | 2547 | 2833 | 4154 | 5269 | 3862 | 3356 |
| EPS in Rs | 17.52 | 18.96 | 19.18 | 29.82 | 31.19 | 34.71 | 51.05 | 65.28 | 48.02 | 41.74 |
| Dividend Payout % | 17 | 16 | 21 | 17 | 16 | 24 | 25 | 25 | 27 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 | 162 |
| Reserves | 12383 | 14068 | 14851 | 15602 | 18165 | 20680 | 23246 | 26545 | 31032 | 34270 |
| Borrowings | 4113 | 4098 | 4316 | 2816 | 2014 | 1056 | 803 | 559 | 438 | 614 |
| Other Liabilities | 4213 | 4346 | 4433 | 4843 | 4514 | 4960 | 5089 | 5267 | 5702 | 7297 |
| Total Liabilities | 20869 | 22673 | 23762 | 23423 | 24855 | 26857 | 29300 | 32533 | 37334 | 42343 |
| Fixed Assets | 9492 | 9950 | 9608 | 9683 | 9516 | 9683 | 9160 | 9607 | 10006 | 12434 |
| CWIP | 1683 | 981 | 676 | 825 | 969 | 766 | 1093 | 1153 | 1566 | 2042 |
| Investments | 973 | 1259 | 2554 | 1471 | 2710 | 2551 | 3662 | 5449 | 7933 | 8223 |
| Other Assets | 8721 | 10483 | 10923 | 11444 | 11661 | 13857 | 15384 | 16323 | 17828 | 19643 |
| Total Assets | 20869 | 22673 | 23762 | 23423 | 24855 | 26857 | 29300 | 32533 | 37334 | 42343 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 2382 | 1463 | 1691 | 3068 | 3755 | 3326 | 3238 | 4134 | 5005 | 3940 |
| Cash from Investing Activity | -1304 | -834 | -1688 | 114 | -2374 | -1858 | -2376 | -2982 | -3682 | -2234 |
| Cash from Financing Activity | -1326 | -385 | -349 | -2949 | -1240 | -1600 | -958 | -1200 | -1293 | -1234 |
| Net Cash Flow | -248 | 243 | -345 | 234 | 141 | -132 | -97 | -49 | 30 | 473 |
| Free Cash Flow | 1284 | 723 | 1187 | 2083 | 2964 | 2645 | 2102 | 2819 | 3490 | 928 |
| CFO/OP | 113 | 77 | 74 | 122 | 113 | 98 | 90 | 91 | 94 | 94 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 65 | 75 | 93 | 83 | 66 | 57 | 65 | 68 | 73 | 73 |
| Inventory Days | 239 | 271 | 250 | 267 | 232 | 230 | 228 | 217 | 231 | 252 |
| Days Payable | 108 | 142 | 123 | 139 | 103 | 108 | 112 | 102 | 116 | 123 |
| Cash Conversion Cycle | 196 | 204 | 220 | 211 | 195 | 180 | 181 | 182 | 188 | 202 |
| Working Capital Days | 99 | 118 | 132 | 113 | 94 | 95 | 113 | 120 | 128 | 106 |
| ROCE % | 7 | 9 | 11 | 12 | 17 | 17 | 18 | 23 | 23 | 15 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 33.47% | 33.47% | 33.47% | 30.91% | 30.92% | 29.19% | 29.2% | 29.19% | 29.21% | 29.21% | 29.21% | 29.21% |
| FIIs | 25.74% | 25.73% | 25.83% | 27.81% | 28.8% | 26.65% | 26.28% | 25.25% | 24.55% | 23.93% | 22.56% | 20.21% |
| DIIs | 24.18% | 24.33% | 24.42% | 24.95% | 23.95% | 27.48% | 27.89% | 28.99% | 29.98% | 30.45% | 31.7% | 34.35% |
| Government | 0% | 0% | 0% | 0% | 0.21% | 0.23% | 0.26% | 0.27% | 0.27% | 0.27% | 0.27% | 0.28% |
| Public | 14.45% | 14.34% | 14.2% | 14.24% | 14.16% | 14.29% | 14.13% | 14.1% | 13.82% | 13.84% | 13.98% | 13.74% |
| Others | 2.16% | 2.12% | 2.08% | 2.09% | 1.95% | 2.15% | 2.23% | 2.2% | 2.16% | 2.29% | 2.28% | 2.2% |
| No. of Shareholders | 426861 | 425731 | 436154 | 463569 | 470234 | 525114 | 543420 | 549655 | 534587 | 540521 | 584217 | 578679 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 3 / 4 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1390.61 | Sell |
| EMA (10) | 1387.52 | Sell |
| SMA (20) | 1408.35 | Sell |
| EMA (20) | 1403.83 | Sell |
| SMA (50) | 1431.04 | Sell |
| EMA (50) | 1415.37 | Sell |
| SMA (100) | 1405.52 | Sell |
| EMA (100) | 1407.13 | Sell |
| SMA (200) | 1389.68 | Sell |
| EMA (200) | 1409.67 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 35.27 | Neutral |
| MACD (12,26,9) | -18.01 | Sell |
| Stochastic (14,3,3) | 11.21 | Buy |
| ADX (14) | 25.18 | Buy |
| Williams %R (14) | -79.25 | Neutral |
| ATR (14) | 22.57 | Neutral |
| ROC (12) | -2.62 | Sell |
| Stoch RSI (14) | 17.89 | Buy |
| UO (7,14,28) | 45.32 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 23 | 62.16% |
| Hold | 10 | 27.03% |
| Sell | 4 | 10.81% |

Based on 37 analyst ratings, observed at 2026-09-11T04:54:38.428945+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06d6216d-6fb6-4cd4-8c70-efb5a1cef2fe.pdf) |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87162d3a-7f86-4282-8634-9c9e2d077c62.pdf) |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ccb8d9c8-9bec-4050-bbd1-15e4b35eff06.pdf) |
| 2026-08-31 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=363f2236-ec4d-4127-8449-14b12b014706.pdf) |
| 2026-08-28 | [Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip Long Island NY USA](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b22a1ba3-d608-45a3-905f-218f0a3aa482.pdf) |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9015cbb0-ae9b-4df7-aaed-8f1520a56d40.pdf) |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Restructuring](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e81e5c7e-abdf-459c-b05b-dbc33ee51660.pdf) |
| 2026-08-26 | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5b2d005c-5562-4682-a439-ef2524c30f12.pdf) |
| 2026-08-25 | [USFDA Inspection At CompanyS Manufacturing Facility In Pithampur India](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=207203d9-f308-4ca5-b56b-b82204f95e15.pdf) |
| 2026-08-19 | [Announcement under Regulation 30 (LODR)-Scheme of Arrangement](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc6caf49-01c4-4548-9381-a58f393a98e6.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-07-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a036a014-e0e9-4194-9a9e-9d44134da589.pdf) |
| 2026-05-15 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85f5f17a-ce72-45a5-9acb-43f1f8c77b27.pdf) |
| 2026-01-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8a642d4a-4e66-484a-a5cd-91e807f955d3.pdf) |
| 2026-01-09 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2734ed52-ea60-4548-95b4-c0d725fae257.pdf) |
| 2025-11-03 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0ea9d3f9-fdfe-4f40-9d9e-057a5018ec8f.pdf) |
| 2025-07-28 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=156e5b80-4621-43c8-8c6c-e3a6dad66b56.pdf) |
| 2025-05-16 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=10726a3d-ea15-40af-9631-9f38ebff5582.pdf) |
| 2025-01-31 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b5ba504e-aacc-4671-a307-9df037b5821a.pdf) |
| 2024-11-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ae36e932-1fad-430d-86cd-068199e717b5.pdf) |
| 2024-07-29 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c9cf2ec8-bbe7-44f5-9ca4-1f635f463676.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-23 | [Financial Results For Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a0ec61c-103f-408a-b30d-44e0f516a473.pdf) |
| 2026-05-13 | [Audited Financial Results And Recommendation Of Final Dividend](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=67c1d826-0069-400e-899e-eaf605d606c1.pdf) |
| 2026-01-23 | [Financial Results For Quarter And Nine Months Ended 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6ad6873c-fc6d-4494-aaf4-34d7911ff637.pdf) |
| 2025-10-30 | [Financial Results For Quarter And Half Year Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5da9ae2d-3fad-47bd-9c16-7149cabe9707.pdf) |
| 2025-07-25 | [Financial Results For Quarter Ended 30Th June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f08b36a2-0581-4ba9-96cd-5af764b25f25.pdf) |
| 2025-05-13 | [Financial Results And Declaration Of Dividend](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=30c83feb-18d5-455c-a921-bcfbe8397753.pdf) |
| 2025-01-28 | [Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended 31St December 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=11d32b86-59af-4fe9-bad6-3470f767c641.pdf) |
| 2024-10-29 | [Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30Th September 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec1880ca-aea1-40fd-9e01-61fccc320562.pdf) |
| 2024-07-26 | [Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=429adf35-76be-42f9-9672-edb640efb339.pdf) |
| 2024-05-10 | [Financial Results And Declaration Of Dividend](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aa97b002-fea6-4b61-ae01-05f871780fa1.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c3c9b3f-1feb-4568-952f-3cf9736654fe.pdf) |
| 2026-05-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d43d827-9448-4991-93f9-cd9fb22fadd6.pdf) |
| 2026-01-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d0318e3b-b31b-41a5-a9ae-adf3337e2e7c.pdf) |
| 2025-10-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b9feb721-cda2-4afe-857c-4ef41a0163e6.pdf) |
| 2025-07-25 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc6f1835-1653-4507-ac88-eb31eff815c9.pdf) |
| 2025-05-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2cc43710-cb55-4a7e-8169-057035373bfe.pdf) |
| 2025-02-18 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=51f89ee5-da9a-4b95-b872-54a7210a0efc.pdf) |
| 2025-01-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ea984e8-ec9f-4d3b-99fb-e0032f4096b6.pdf) |
| 2024-10-29 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9762241-7185-496e-b99f-3ddc08994970.pdf) |
| 2024-07-26 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8074c100-061a-4a7d-9a48-d92bc1053531.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-23 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ffb4e15-5803-4c14-8fb8-7304d2db6e00.pdf) |
| 2026-05-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=362a2267-bd57-4beb-8067-8d146998d1d9.pdf) |
| 2026-01-23 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab04a40b-2b83-4129-ab9d-e97511de4b0d.pdf) |
| 2025-10-30 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b79178e9-1666-4751-a5a8-64fc1b319fa7.pdf) |
| 2025-07-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=baafd099-3ed9-4f51-b47e-707099a51dd0.pdf) |
| 2025-05-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5655b9f-ed2a-4c43-b3c5-57364fbba994.pdf) |
| 2024-10-29 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66e9ead6-5060-43f5-ab9c-f36b54d10217.pdf) |
| 2024-07-26 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2415f1f-97d9-4317-b266-227b64e72266.pdf) |
| 2024-05-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=304ef385-51d8-4ba4-9e51-500dc1a86c6b.pdf) |
| 2024-01-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50a28189-e8d2-4c15-8d97-89264c7ecb47.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Mar - Cipla USA recalls unexpired Lanreotide Injection batches, causing temporary market supply disruption (09-Mar-2026). | [Update On US Food And Drug Administration (USFDA) Inspection On Pharmathen International S.A. 9 Mar - Cipla USA recalls unexpired Lanreotide Injection batches, causing temporary market supply disruption (09-Mar-2026).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2f47f254-c4df-492e-96b6-f2700ee8f39e.pdf) |
| 6h - Pradeep Bhadauria resigns as Global Chief Scientific Officer of Cipla USA; last day 31 March 2026. | [General Updates 6h - Pradeep Bhadauria resigns as Global Chief Scientific Officer of Cipla USA; last day 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a5035df5-a103-4669-87c8-981a42600def.pdf) |
| 6 May - Newspaper publication under Regulation 30 of SEBI (LODR) Regulations, 2015 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 6 May - Newspaper publication under Regulation 30 of SEBI (LODR) Regulations, 2015](https://www.bseindia.com/xml-data/corpfiling/AttachLive/fe3b0c09-486d-40c8-aef0-bc044d674c1b.pdf) |
| 4 Feb - Board meeting on 13 Feb 2026 to approve unaudited results for quarter ended 31 Dec 2025; trading window closed. | [Board Meeting Intimation for Intimation Under Regulation 29(1) Of SEBI (LODR) Regulations, 2015 4 Feb - Board meeting on 13 Feb 2026 to approve unaudited results for quarter ended 31 Dec 2025; trading window closed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/536e04a4-8188-4239-b873-0fc4ecf7bd15.pdf) |
| 31 Mar - Board meeting 13 May 2026 to approve audited FY26 results and consider final dividend; trading window Apr 1–May 15. | [Board Meeting Intimation for The Quarter And Year Ended 31St March, 2026 Under SEBI (LODR) Regulations, 2015 31 Mar - Board meeting 13 May 2026 to approve audited FY26 results and consider final dividend; trading window Apr 1–May 15.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f18ac7b0-351c-4057-8acd-e10fb5e04197.pdf) |
| 30 Mar - Umang Vohra resigned effective 1 Apr 2026; Achin Gupta assumed MD & Global CEO; two SMPs appointed. | [Announcement under Regulation 30 (LODR)-Change in Management 30 Mar - Umang Vohra resigned effective 1 Apr 2026; Achin Gupta assumed MD & Global CEO; two SMPs appointed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/352ea597-7304-4583-bb08-741f48e3e38e.pdf) |
| 30 Mar - Achin Gupta assumed MD & Global CEO; Umang Vohra resigned effective 1 April 2026; two SMPs appointed 1 April 2026. | [Announcement under Regulation 30 (LODR)-Resignation of Director 30 Mar - Achin Gupta assumed MD & Global CEO; Umang Vohra resigned effective 1 April 2026; two SMPs appointed 1 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/12a0e322-15c0-46fa-9c8d-580dada51509.pdf) |
| 28 Mar - Newspaper publication regarding opening of special window of lodgement of transfer and dematerialisation of physical shares. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Mar - Newspaper publication regarding opening of special window of lodgement of transfer and dematerialisation of physical shares.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/015bcbfb-2f2e-470d-92dd-39264e4482c9.pdf) |
| 26 Mar - Members approved Achin Gupta as MD & Global CEO, remuneration; PR Ramesh re-appointed, passed 25 Mar 2026. | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 26 Mar - Members approved Achin Gupta as MD & Global CEO, remuneration; PR Ramesh re-appointed, passed 25 Mar 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ee13ff6-0fe0-4679-bf2e-90f2e83ce99f.pdf) |
| 26 Feb - ESG rating downgraded 66→65 for FY2024–25; received 25 Feb 2026; linked to Cipla USA recall. | [Intimation Under Regulation 30 Read With Schedule III Of The SEBI (LODR) Regulations, 2015 26 Feb - ESG rating downgraded 66→65 for FY2024–25; received 25 Feb 2026; linked to Cipla USA recall.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e48b0a25-d4fc-431a-b8df-3039a2eaeebd.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6dc9897-3c64-4c9e-bdd2-2c4734877009.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0ea9d3f9-fdfe-4f40-9d9e-057a5018ec8f.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ae36e932-1fad-430d-86cd-068199e717b5.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/85f5f17a-ce72-45a5-9acb-43f1f8c77b27.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/85f5f17a-ce72-45a5-9acb-43f1f8c77b27.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/10726a3d-ea15-40af-9631-9f38ebff5582.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/20e05c47-5d65-4cae-8e80-3fd901068efa.pdf) |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/156e5b80-4621-43c8-8c6c-e3a6dad66b56.pdf) |
| Jul 2024 | [Concall - Jul 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c9cf2ec8-bbe7-44f5-9ca4-1f635f463676.pdf) |
| Jan 2026 | [Concall - Jan 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8a642d4a-4e66-484a-a5cd-91e807f955d3.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4070b137-2a68-4790-8821-268ff7c4e408.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/674f8305-0979-4722-ad6c-b7915c00c1d8.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/08bf88a4-c32a-45df-826f-d749bbfcd2b3.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9ec11f08-4ca3-4060-8cd4-2cfad0af4959.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/39aa9a87-4be0-4161-806e-8b1cd2471033.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:20:03.376Z.